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Abstract
Ultrasound scanning of bladder volume is used for prevention of postoperative urinary retention (POUR). Accurate assess-
ment of bladder volume is needed to allow clinical decision-making regarding the need for postoperative catheterization. 
Two commonly used ultrasound devices, the BladderScan® BVI 9400 and the newly released Prime® (Verathon Medical®, 
Bothell, WA, USA), with or without the ‘pre-scan’ option, have not been validated in clinical practice. The aim of this study 
was to assess the performance of these devices in daily clinical practice. Between June and September 2016 a prospective 
observational study was conducted in 318 surgical patients (18 years or older) who needed a urinary catheter perioperatively 
for clinical reasons. For acceptable performance, we required that the volume as estimated by the BladderScan® differs by 
no more than 5% from the actual urine volume after catheterization. The Schuirmann’s two one-sided test was performed 
to assess equivalence between the BladderScan® estimate and catheterization. The BVI 9400® overestimated the actual 
bladder volume by + 17.5% (95% CI + 8.8 to + 26.3%). The Prime® without pre-scan underestimated by − 4.1% (95% CI 
− 8.8 to + 0.5%) and the Prime® with pre-scan underestimated by − 6.3% (95% CI − 11.6 to − 1.1%). This study shows 
that while both ultrasound devices were able to approximate current bladder volume, both BVI 9400® and Prime®—with 
and without pre-scan—were not able to measure the actual bladder volume within our predefined limit of ± 5%. Using the 
pre-scan feature of the Prime® did not further improve accuracy.
Keywords Bladder catheterization · Bladder volume · Post operative urinary retention · Ultrasound BladderScan · 
Validation
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1 Introduction
Transabdominal ultrasound is frequently used for measur-
ing bladder volumes non-invasively to prevent postopera-
tive urinary retention (= POUR) by timely catheterization, 
but also to avoid unnecessary bladder catheterizations 
[1–4]. Bladder catheterization is the “standard” treatment 
for POUR [1, 5, 6], but it is an invasive procedure that 
contributes to an increased risk of urinary tract infections, 
urethral trauma, patient discomfort and unplanned and 
prolonged hospital admissions [7–10]. Adequate monitor-
ing of postoperative bladder volumes is mandatory to limit 
the risks associated with prolonged bladder overdistension 
or bladder catheterization [1, 2, 11, 12].
The BladderScan® (Verathon®, Bothell, WA, USA) 
is a dedicated ultrasound device to clinically determine 
bladder volumes. The two latest editions of the Bladder-
Scan® are the BVI 9400® and its successor the Prime®. 
Although both devices are CE marked and widely used 
in hospitals, the performance of their algorithms has 
never been validated in a perioperative clinical setting. 
The Prime® has the possibility to use a pre-scan function, 
showing real time echo images of the bladder next to the 
normally displayed scanned bladder. The aim of this pre-
scan function is to improve accuracy.
The manufacturer of the BladderScan® claims an accu-
racy of ± 15% ± 15 mL. We, a priori, defined adequate 
clinical performance when the estimated volume differs 
from the actual urine volume after catheterization by no 
more than 5%, based on clinical literature [13–15]. The 
aim of this study is to validate the performance of the 
BVI 9400® and the Prime® (with and without pre-scan) 
in surgical patients by assessing the difference between 




After institutional ethical approval, an investigator initi-
ated prospective study was conducted between June and 
September 2016 in three groups of at least 100 consecutive 
surgical patients, each requiring bladder catheterization. All 
patients gave written informed consent. Bladder volumes 
were assessed using either the non-invasive BladderScan 
BVI 9400® or the Prime®, with or without a pre-scan. Fol-
lowing the non-invasive estimation of the bladder volume 
all patients underwent urinary catheterization during which 
the actual urine volume was assessed as the “gold standard”.
2.2  Patient selection procedure
Two groups of surgical patients (18 years or older, ASA 
classification I–IV), who required a perioperative bladder 
catheter following standard clinical hospital protocols, were 
included. The first group of patients consisted of surgical 
patients who needed a catheter after induction of anaesthe-
sia and prior to the start of surgery due to expected volume 
shifts, epidural anaesthesia, or surgery in the smaller pelvis 
for example during coronary arterial bypass graft (CABG) 
surgery, orthopaedic hip or knee prostheses surgery or 
colonic surgery (“Perioperative Urinary Catheterization 
Protocol” Medical Center Leeuwarden). The second group 
of patients consisted of postoperative patients at the post 
anaesthesia care unit (PACU) who were unable to void spon-
taneously and needed a catheter to prevent bladder overdis-
tension (bladder volume ≥ 500 mL, “Micturition Protocol” 
Medical Center Leeuwarden). Exclusion criteria were a sur-
gical incision in the suprapubic region, abdominal ascites, 
and pregnancy. Furthermore, surgical patients with an actual 
catheterized volume ≤ 30 mL in the operating theatre were 
excluded for analysis, as the BladderScan® is not sensitive 
to detect bladder volumes ≤ 30 mL (based on the information 
from the manufacturer).
2.3  Sample size
Based on previous studies we hypothesized that the esti-
mated volume by the BladderScan® devices differs from 
the volume after catheterization by no more than 5% [13, 
15]. With the predefined margin of equivalence of ± 5% and 
an assumed correlation of 0.90, a sample size of at least 92 
pairs per study group was needed to achieve 90% power to 
detect equivalence [16].
2.4  Study procedure
The researchers (CB or TAB) or operation nurses in the 
operating theatre and PACU performed all the measure-
ments. They were trained in the use of the Prime® by an 
instructor of the manufacturer. Included patients with a 
clinical indication for intraoperative bladder catheteriza-
tion were asked not to void shortly before the time of the 
surgery to ensure a measurable bladder volume. After induc-
tion of anaesthesia, three consecutive ultrasound measure-
ments (scans) were performed in the supine position using 
the BladderScan® device in accordance with the cohort the 
patient was included. After three non-invasive measurements 
with each type of the BladderScan®, the patient was directly 
catheterized to measure the actual bladder volume. The first 
device to start with was the BVI9400®, by measuring blad-
der volumes non-invasively in 100 or more consecutive 
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patients. After at least 100 patients were included with the 
BVI9400®, the next device used was the Prime® without 
pre-scan for measuring bladder volume in at least 100 con-
secutive patients. Again, after more than 100 patients were 
included with the Prime® without pre-scan, the Prime® with 
pre-scan function was used for measuring bladder volume 
non-invasively in at least 100 consecutive patients.
In included patients requiring postoperative bladder 
catheterization, the BVI 9400® was used at the PACU in 
accordance with the local hospital protocol (= postopera-
tive bladder catheterization is indicated when the scanned 
bladder volume is larger than the threshold of 500 mL and 
the patient is unable to void spontaneously). If this was the 
case during the study period, then three consecutive meas-
urements in the supine position were performed with the 
type of BladderScan® which was momentarily used in the 
intraoperative group of surgical patents measured in the OR, 
which were in following order; the BVI 9400®, the Prime® 
without pre-scan and the Prime® with pre-scan.
With the BVI 9400® and Prime® without pre-scan, the 
aiming circle on the display was used to guide the position 
of the probe. In the Prime® with pre-scan, the “real echo” 
pre-scan image was developed to guide the position of the 
probe. By changing the position of the probe, a green line 
is trying to encircle the whole bladder echo image. If this 
was the case, this image could be fixed and a BladderScan 
was followed, assuming that the best image would lead to 
the best result = measuring the total bladder with the larg-
est bladder volume. A print of each measurement was col-
lected to assess which of the three measurements was the 
“best” BladderScan® estimate, defined as the largest and 
most centrally displayed bladder together with the highest 
scanned volume. In all patients, catheterization took place 
immediately after the scanning procedure. The actual cath-
eterized urine volumes were collected in a calibrated bowl. 
A 60 mL syringe was used to retrieve the last millilitres of 
urine to assess the precise volume and to be sure the bladder 
was completely emptied.
2.5  Outcomes
The primary outcome was the difference in volume in mL 
between the “best” estimated bladder volume measured with 
the BladderScan®, using the three different methods (BVI 
9400®, Prime® without pre-scan, and Prime® with pre-
scan) versus the actual measured urine volume after cath-
eterization. In this, the difference between estimated and 
actual catheterized volume was expressed as the percentage 
of the actual catheterized volume.
Secondary outcomes included the difference in volume 
between the best estimated and the actual measured urine 
volume after catheterization over the small to large volume 
range (≤ 400 and > 400 mL). We choose 400 mL, because 
volumes smaller than 400 mL are considered safe, not lead-
ing to bladder distention. Above 400 mL, bladder volumes 
have to be measured non-invasively at regularly intervals 
to prevent bladder distention. In literature different volume 
limits are used for urinary retention (400, 500 or 600 mL) 
[3, 17, 18]. These commonly used volume limits are used to 
calculate the proportion of correct decisions to catheterize, 
after measuring the bladder volume non-invasively.
Furthermore, homogeneity of outcome in different patient 
subgroups was evaluated for gender, age, and BMI.
2.6  Statistical analysis
All data are expressed as mean ± SD for normally distributed 
data and median with range for skewed data. Normality was 
assessed by visual inspection and the Shapiro–Wilk test.
For the primary outcome, the Schuirmann’s two one-
sided test was used. For the secondary outcome, Bland–Alt-
man analyses were performed to assess the level of agree-
ment between the BladderScan® estimate and the actual 
volume after catheterization over the full range of volumes 
and over the two volume ranges of ≤ 400 and > 400 mL [19].
To evaluate the performance of the devices with regard to 
correct clinical decision making the proportion true positives 
and true negatives were analysed. A Student’s t test was used 
to evaluate differences between groups for normally distrib-
uted data, or a Mann–Whitney U test for non-normality. A 
one-way independent ANOVA or Kruskall-Wallis test was 
performed in case of a three-group comparison, depending 
on the normality of the data. For qualitative parameters, 
comparisons between groups were evaluated using Fisher 
exact test (dichotomous response) or Chi square test (exact 
when indicated). Preplanned subgroup analyses consisted 
of demographic characteristics that might influence the 
accuracy of the BladderScan®: gender (male vs. female), 
age (< 60 years vs. ≥ 60 years), and BMI (< 25 kg/m2 vs. 
25–30 kg/m2 vs. ≥30 kg/m2). A 2-tailed p-value less than 
0.05 was considered statistically significant. All analyses 
were performed using commercially available computer 
software (Statistical Analysis System version 9.4, SAS Insti-
tute, Cary, NC, USA).
3  Results
Between June 2016 and September 2016, 392 consecutive 
patients were evaluated for participation in this study of 
which 345 were included. Of these, 318 patients were avail-
able for analysis (Fig. 1, Flow Chart).
Table 1 presents the demographic characteristics of the 
patients included. No statistically significant differences 
between the cohorts were observed at baseline, except for 
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number of patients measured postoperatively. In the cohort 
of the BVI 9400® significant more patients were assessed 
postoperatively compared to the cohort of both Primes (15, 
3 and 9% respectively, p = 0.003). In addition, measured 
bladder volumes (estimated and actual) are presented for 
all three cohorts.
3.1  Primary outcome
3.1.1  Equivalence of bladder volume estimates
For the primary endpoint of equivalence of bladder vol-
ume estimates, in all three cohorts the equivalence was not 
established. Over the whole volume range, the BVI 9400® 
Fig. 1  Flow-chart patient selection
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overestimated the actual bladder volume by an average of 
+ 17.5% (95% CI + 8.77 to + 26.31, p = 1.00). The Prime® 
without pre-scan underestimated the actual bladder volume 
by an average of − 4.1% (95%CI − 8.78 to + 0.49, p = 0.36) 
and the Prime® with pre-scan underestimated the actual 
bladder volume by an average of − 6.3% (95% CI − 11.57 
to − 1.07, p = 0.69) (Table 2).
3.1.2  Level of agreement
The BVI 9400® overestimates the actual bladder volume 
with a bias of + 21.8 mL and limits of agreements (LOA) of 
− 99 mL to + 140 mL Both Prime® devices demonstrated 
a significant bias towards underestimation (both with and 
without performing a pre-scan, bias = − 20.7 mL) and wide 
limits of agreement (− 183 to + 141 mL) (Fig. 2).
3.2  Secondary outcomes
3.2.1  Subgroup analyses for homogeneity of BladderScan® 
performance
As presented in Table 3, subgroup analysis for the homo-
geneity of the performance of the BladderScan® over dif-
ferent subgroups, showed that equivalence was not reached 
in any of the predefined subgroups. Although not reaching 
equivalence, some differences between subgroups were 
observed. For example, for the Prime® without and with 
pre-scan function, the underestimation in male patients was 
− 0.8 and + 0.2% respectively, almost reaching equivalence 
(p = 0.08). In patients with a BMI < 25 kg/m2 both Primes 
modes performed well, with an underestimation of − 0.5 
and − 2.7% respectively, but still not reaching equivalence 
(p = 0.112 and 0.266).
For the BVI 9400® used in patients with smaller or 
larger bladder volumes than 400 mL the overestimation 
decreased from + 22% in patients with an actual bladder 
volume ≤ 400 mL (N = 79) to + 3.5% in patients with an 
actual bladder volume > 400  mL (N = 26). In contrast, 
in the Prime® without pre-scan the underestimation 
increased from − 2.7% in patients with an actual bladder 
volume ≤ 400 mL (N = 95) to − 13.1% in patients with an 
actual bladder volume > 400 mL(N = 15). For the Prime® 
with pre-scan the underestimation increased from − 5.0% in 
patients with an actual bladder volume ≤ 400 mL (N = 87) to 
− 13.6% in patients with an actual bladder volume > 400 mL 
(N = 16).
Addressing the level of agreement using the 
Bland–Altman method showed the same results: the BVI 
9400® showed less bias with bladder volumes > 400 mL 
(bias = + 10.0  mL) than with smaller bladder vol-
umes ≤ 400 mL (bias = + 25.7 mL). For the Prime® device 
in both modes this was reversed: in patients with bladder 
volumes ≤ 400 mL the bias was − 7.9 and − 4.0 mL and 
for patients with bladder volumes > 400 mL the bias was 
− 101.5 and − 111.8 mL for the Prime® without and with 
pre-scan respectively (Table 4).
3.2.2  Consequences for clinical decision-making
With the BVI 9400®, the proportion true negative (= blad-
der volume measured and actual bladder volume both 
≤ 500 mL) and true positive (= bladder volume measured 
and actual bladder volume both > 500 mL) clinical decisions 
whether or not to catheterize the bladder (using a threshold 
of 500 mL) was 1.00 (95%CI 0.96–1.00) and 0.91 (95% CI 
0.79–1.00), respectively. Comparable results were found 
with the Prime® without pre-scan 0.96 (95% CI 0.92–1.00) 
and 0.86 (95% CI 0.60–1.00) respectively and the Prime® 
with pre-scan 0.94 (95%C I 0.87–0.98) and 1.00 (95% CI 
0.64–1.00) respectively (Table 5).
Table 1  Demographic 
characteristics
BMI  body mass index
Patient data BVI 9400 (n = 105) Prime without pre-scan 
(n = 110)
Prime with pre-scan 
(n = 103)
p value
Women no. (%) 52 (49.5) 42 (38.2) 47 (45.6) 0.23
Age mean (SD) (year) 65.9 (13.4) 66.6 (12.5) 64.5 (12.4) 0.41
Age < 60, no. (%) 31 (29.5) 26 (23.6) 29 (28.2) 0.61
Weight (mean) (kg) 80.4 (17.0) 82.9 (15.5) 82.0 (14.7) 0.37
Height (mean) (cm) 172.4 (9.3) 174.3 (9.1) 174.5 (8.9) 0.14
BMI (mean) (kg/m2) 27.0 (4.8) 27.2 (4.2) 27.0 (4.6) 0.88
BMI < 25 no. (%) 38 (36.2) 40 (36.4) 38 (36.9) 0.97
≥25 BMI < 30 no. (%) 44 (41.9) 45 (40.9) 39 (37.9)
BMI ≥ 30 no. (%) 23 (21.9) 25 (22.7) 26 (25.2)
Uterus no. (%) 46 (88.5) 37 (88.1) 39 (83.0) 0.71
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4  Discussion
In this study, the performance of the BladderScan BVI 
9400® and its successor Prime® were assessed in surgical 
patients, both perioperative and postoperative. The estimates 
of bladder volumes were compared with actual bladder vol-
umes collected after catheterization, which is considered the 
“gold standard” for measuring urinary volumes.
We a-priori set the margin of equivalence for a clinically 
acceptable estimation of the bladder volume to ± 5%, based 
on the literature in which a mean difference of − 7% with 
the BVI 2500® and a mean difference of − 3.3% with the 
BVI 3000®, an earlier version of the BladderScan, were 
observed [13, 15]. In neither the BVI 9400® nor the Prime® 
(with or without pre-scan option used) the performance was 
within our margin of equivalence. In this, the BVI 9400® 
structurally overestimated the actual bladder volume and the 
Prime® without and with pre-scan structurally underesti-
mated actual bladder volume. Underestimation may be pre-
ferred considering the fact that postoperative catheterization 
is a complication patients would like to avoid, but only if a 
strict “bladder protocol” is used to prevent bladder overd-
istension. Overestimation of the actual bladder volume will 
lead to earlier and more unnecessary postoperative urinary 
catheterizations [20].
When using the manufacturer’s claim of an accuracy 
(± 15% ±15 mL) for the BVI 9400® and the Prime®, the 
amount of overestimation of the BVI 9400® was still beyond 
that level of accuracy. For the Prime® (both with or with-
out pre-scan) the amount of underestimation was within the 
manufacturers’ claim.
In clinical practice, a measured bladder volume of 
500 mL, which is considered a clinical cut-off value for 
bladder catheterization, should ideally not deviate more 
than 5% from the true bladder volume (i.e., between 475 and 
525 mL), because in this range the BladderScan® can help 
the clinician in clinical decision-making. The manufacturer 
claims an accuracy of ± 15% ± 15 mL, both for the BVI 
9400® and the Prime® (i.e. between 410 and 590 mL). This 
is a rather large volume range, especially when the decision 
is whether or not to catheterize.
A possible explanation of these differences in the results 
between the BVI 9400® (overestimating and performing 
better in bladder volumes > 400 mL), and both Prime’s 
(underestimating and performing better in bladder vol-
umes ≤ 400 mL) could be that the BVI 9400® is using 
another, older algorithm, based on earlier devices such as the 
BVI 3000®. The Prime® uses a new developed algorithm, 
which has only been tested in phantoms in the factory and 
not on patients.
When expressing the error in BladderScan® estimates 
in millilitres, using the Bland–Altman method, the mean 
bias was relatively small (+ 22 mL for the BVI 9400® and 
− 21 mL for both modes of the Prime®). Previous studies 
investigating the accuracy of older models of the BVI (BVI 
2500®/2500®+, BVI 3000®) have reported similar mean 
errors (bias) ranging from − 21.5 to + 19 mL [13–15]. 
However, the limits of agreement in both the BVI 9400® 
and Prime® were large in bladder volumes > 400  mL 
(range > 340 mL for all three scanners) indicating a high 
variability between individual subjects towards both 
under- and overestimation. This was also reflected in the 
lack of equivalence in all three cohorts.
Additional subgroup analyses did not show significant 
differences between volumes ≤ 400 and > 400 mL. How-
ever, in patients with bladder volumes > 400 mL the BVI 
9400® tends to perform better with an average overesti-
mation of 3.5% compared to 17.5% over the entire volume 
range. In the Prime® this was not observed; the average 
underestimation increased when measuring bladder vol-
umes > 400 mL (to almost − 14%). Although not reach-
ing statistical significance, these results suggest that BVI 
9400® estimates are more accurate in the higher volume 
range, whereas the Prime® appears to perform better in 
the lower volume range. Previous studies also reported 
higher discrepancies between the BladderScan® estimate 
and catheterization in actual bladder volumes of less than 
50–100 mL and larger than  400mL19. Nonetheless, in all 
Table 2  Actual and estimated 
bladder volumes measured BVI 9400 (n = 105) Prime with-out pre-scan 
(n = 110)
Prime with Pre-
scan (n = 103)
p value
Estimated volume, mean (SD) (mL) 288 (237.0) 191 (163.7) 203 (182.1) < 0.001
Actual volume, mean (SD) (mL) 266 (241.9) 212 (202.8) 224 (226.6) 0.18
Difference estimated–actual volume, 
mean (SD) (mL)
21.8 (59.9) − 20.7 (70.1) − 20.7 (82.7) < 0.001
Preoperative measurement, no (%) 89 (84.8) 107 (97.30) 94 (91.3) 0.005
Actual volumes > 400 mL, no (%) 26 (24.8) 15 (13.6) 16 (15.5) 0.078
Actual volumes > 500 mL, no (%) 17 (16.2) 9 (8.2) 14 (13.6) 0.194
Actual volumes > 600 mL, no (%) 11 (10.5) 4 (3.6) 8 (7.8) 0.149
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three BladderScans the large variability did not have a 
strong impact on the occurrence of unnecessary (true posi-
tives ≥ 80%) or missed (true negatives ≥ 94%) catheteriza-
tions, although the numbers of patients with higher bladder 
volumes were too small to draw meaningful conclusions.
We expected that the Prime® with pre-scan ability 
would improve the accuracy of the measured bladder 
volume. Using real-time echo image should help to scan 
the whole bladder. In clinical practice this image was 
unsteady, and it was difficult to encircle the whole blad-
der with the green line. Therefore, the pre-scan function 
felt unreliable. It was surprising to find minimal differ-
ences between the Prime® without and with pre-scan. In 
fact, slightly better results were observed when using the 
Prime® without pre-scan, suggesting that using the pre-
scan feature does not improve accuracy.
We also demonstrated that age or BMI did not signifi-
cantly affect the accuracy of the BladderScan®. However, 
with the Prime®, we observed more accurate results in 
males. Previous studies also found that the BladderScan® 
(BVI 2500®/2500®+) was more accurate in males than 
females [13, 21], suggesting that the algorithm for female 
patients may need to be improved. Also, in patients with 
small BMI’s (< 25 kg/m2) the BVI 9400® had difficulty in 
scanning the entire bladder (mean + 20.2 mL) particularly 
with larger bladder volumes. The display of the device and 
its printouts showed that parts of the bladder were outside 
the scanning area with measured values labeled “larger 
than” (>) instead of “is” (=). Possibly, in lean patients 
the scanhead is positioned too close to the bladder, which 
prevents the device from scanning the whole bladder. This 
was not the case with the Prime®. In female patients and 
patients with a BMI ≥ 25 kg/m2 these effects were less 
pronounced. Overall, our results suggest that the newer 
algorithms are more accurate in subgroups of patients 
(male patients and patients with a BMI < 25 kg/m2), but 
still need improvement.
The strength of this study is that it was performed in a 
large number of unselected patients requiring bladder cath-
eterization in a daily clinical practice setting. The same 
trained researcher (CvdB) performed more than 80% of the 
measurements eliminating inter-observer bias. This might 
potentially limit the generalizability of our findings for set-
tings where the measurements are performed by many dif-
ferent nurse operators—with varying experience in bladder 
ultrasound scanning. However, inter-observer reliability 
has been investigated in several previous studies and was 
found to be high [22–24]. Previous studies also showed 
that repeated measures do not improve the accuracy of 
the BladderScan® and that the results are independent of 
patient position and experience of the examiner [24, 25]. 
Another limitation of our study is that we did not include 
many patients with bladder volumes larger than 500 mL. 
Fig. 2  a Bland–altman plot displaying the level of agreement of the Blad-
derScan® Bvi 9400 over the whole volume range. b Bland–altman plot 
displaying the level of agreement of the prime® without pre-scan over the 
whole volume range. c Bland–altman plot displaying the level of agree-
ment of the prime® with pre-scan over the whole volume range. Plotted 
is the average of the measured volume plus the scanned volume (X-axis), 
versus the difference of the measured volume minus the scanned volume 
(Y-axis). Blue horizontal line indicates the mean difference (= bias), and 
the green horizontal lines indicate two times standard deviation (= preci-
sion)
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Therefore, our findings with regard to the performance 
of the BladderScan® in the higher volume ranges and in 
correct clinical decision-making, need to be interpreted 
with caution.
5  Conclusion
This study showed that the ultrasound devices BVI 9400® 
and Prime® with and without pre-scan were not able to 
measure the actual bladder volume within our strict prede-
fined limits of ± 5%. However, the BVI 9400® performed 
better in bladder volumes > 400 mL and the Prime® per-
formed better in bladder volumes ≤ 400 mL, in male patients 
and in patients with a BMI < 25 kg/m2. The pre-scan feature 
of the Prime® did not improve accuracy. Taken together, this 
suggests that the algorithms for measuring bladder volume 
non-invasively can be further improved, helping the clini-
cian in making the right decision whether or not to cath-
eterize, not too early (= unnecessary) but certainly not too 
late (= preventing bladder distention). An important lesson 
learnt is that new devices should be validated in clinical 
practice, on real patients, before they are sold to the market. 
On the other hand, despite their limited accuracy, the studied 
Table 3  primary and secondary outcomes and differences in percentages by patient characteristics and bladder volume ≤ 400 and > 400 ml
Numbers in percentages (%) + standard deviation (SD)
Age in years
BMI  body mass index (kg/m2), CI confidence interval
BVI 9400 Prime without pre-scan Prime with pre-scan
Mean 95% CI p Mean 95% CI p Mean 95% CI p
Overall 17.5 (45.3) 8.77 to 26.31 0.997 − 4.1 (24.5) − 8.78 to 0.49 0.357 − 6.3 (26.9) − 11.57 to − 1.07 0.690
Male 19.8 (49.5) 6.18 to 33.48 0.983 − 0.8 (24.5) − 6.71 to 5.16 0.080 0.2 (25.6) − 6.67 to 7.03 0.082
Female 15.2 (41.0) 3.80 to 26.61 0.961 − 9.6 (23.8) − 17.02 to − 2.17 0.891 − 14.1 (26.5) − 21.85 to − 6.261 0.998
Age > 60 year 16.4 (33.9) 3.95 to 28.82 0.964 − 2.1 (26.6) − 12.84 to 8.61 0.292 − 7.2 (25.7) − 16.93 to 2.61 0.673
Age ≤ 60 year 18.0 (49.5) 6.55 to 29.50 0.987 − 4.8 (24.0) − 9.98 to 0.44 0.465 − 6.0 (27.5) − 12.35 to 0.38 0.621
BMI ≤ 25 20.2 (56.1) 1.77 to 38.66 0.948 − 0.5 (22.8) − 7.83 to 6.74 0.112 − 2.7 (22.7) − 10.13 to 4.77 0.266
25 < BMI ≤ 30 14.4 (45.6) 0.54 to 28.24 0.911 − 6.4 (25.2) − 13.99 to 1.12 0.648 − 8.3 (28.7) − 17.58 to 1.05 0.759
BMI > 30 19.1 (17.9) 11.39 to 26.90 0.999 − 5.8 (26.4) − 16.68 to 5.12 0.558 − 8.7 (30.0) − 20.82 to 3.40 0.733
≤ 400 mL 22.2 (50.9) 10.75 to 33.55 0.998 − 2.7 (25.1) − 7.86 to 2.38 0.191 − 5.0 (28.3) − 11.0 to 1.05 0.497
> 400 mL 3.5 (13.8) − 2.04 to 9.10 0.296 − 13.1 (18.6) − 23.32 to − 2.78 0.943 − 13.6 (16.0) − 22.16 to − 5.08 0.976
Table 4  Bland–altman 
analysis over the two volume 
ranges ≤ 400 and > 400 mL by 
type of BladderScan®
Bias = average of actual volume ^ scanned volume (mL)
LOA level of agreement (mL)
Volumes ≤ 400 mL Volumes > 400 mL
N Bias LOA N Bias LOA
BVI 9400 79 25.7 − 69 to 121 26 10.0 − 159 to 179
Prime without pre-scan 95 − 7.9 − 81 to 65 15 − 101.5 − 385 to 182
Prime with pre-scan 87 − 4.0 − 72 to 64 16 − 111.8 − 447 to 223
Table 5  The proportion well predicted clinical decisions whether or not to catheterize at a threshold of 400, 500, and 600 ml, by type of Blad-
derScan®
Data are presented as percentage (95% confidence interval)
400 mL 500 mL 600 mL
True negatives True positives True negatives True positives True negatives True positives
BVI 9400 100 (1.00–1.00) 89.7 (0.79–1.00) 100 (1.00–1.00) 90.9 (0.79–1.00) 98.9 (0.97–1.00) 80.0 (0.60–1.00)
Prime without pre-scan 97.9 (0.95–1.00) 87.5 (0.71–1.00) 96.1 (0.92–1.00) 85.7 (0.60–1.00) 98.1 (0.96–1.00) 100 (1.00–1.00)
Prime with pre-scan 97.7 (0.94–1.00) 82.4 (0.64–1.00) 93.7 (0.87–0.98) 100 (1.00–1.00) 96.0 (0.92–1.00) 100 (1.00–1.00)
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devices adequately facilitated clinical decision making when 
the decision is at hand whether it is necessary to catheterize 
the patient, especially when bladder volumes were 500 mL 
or more.
Author Contributions TAB Study design, patient recruitment, data 
collection, data analysis and interpretation, first author. CvdB Study 
design, patient recruitment, data collection, data analysis and interpre-
tation, second author. ENvR Study design, analysis and interpretation 
data, critical revision of manuscript. CJK Study design, interpretation 
of data, critical revision of manuscript. NV Study design, data analysis 
and interpretation data, critical revision of manuscript.
Funding This work was supported by Verathon®, Global Headquarters 
Verathon Inc. 20001 North Creek Parkway, Bothell, WA 98011 USA. 
Financial support was used for financing the research assistant (CvdB) 
and for data analysis.
Compliance with ethical standards 
Conflict of interest Verathon® supplied the study with an unrestricted 
grant for financing the implementation of the study (research assis-
tant, data collection and data analysis). Verathon® had no influence on 
study design, on data collection and interpreting data, nor on the final 
draft or where to submit the paper. They trained medical personal in 
the BVI9400® and the Prime® with and without prescan following the 
rules of using new Medical Technology in the Hospital (Dutch law). 
They were informed on the progress of the study. T.A. Brouwer, has 
received a travel grant for a clinical lecture about POUR for Verathon® 
sales marketers, but no other payments. Charina van den Boogaard, 
research assistant, was financial supported by the hospital. All other 
authors have no conflict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Baldini G, Bagry H, Aprikian A, Carli F. Postoperative urinary 
retention: anesthetic and perioperative considerations. Anesthe-
siology. 2009;110:5:1139–57.
 2. Darrah DM, Griebling TL, Silverstein JH. Postoperative urinary 
retention. AnesthesiolClin. 2009;27(3):465–84.
 3. Brouwer TA, Rosier PF, Moons KG, Zuithoff NP, van Roon EN, 
Kalkman CJ. Postoperative bladder catheterization based on 
individual bladder capacity: a randomized trial. Anesthesiology. 
2015;122(1):46–54.
 4. Ozturk NK, Kavakli AS. Use of bladder volume measurement 
assessed with ultrasound to predict postoperative urinary reten-
tion. North Clin Istanb 2017 20;3(3):209–16.
 5. Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez Guerra L, 
Hong SJ, El Khalid S, World Study Group, et al. Management of 
acute urinary retention: a worldwide survey of 6074 men with 
benign prostatic hyperplasia. BJU Int. 2012;109:1:88–95.
 6. Halleberg Nyman M, Gustafsson M, Langius-Eklof A, Johans-
son JE, Norlin R, Hagberg L. Intermittent versus indwelling 
urinary catheterisation in hip surgery patients: a randomised 
controlled trial with cost-effectiveness analysis. IntJNursStud. 
2013;50(12):1589–98.
 7. Tammela T, Kontturi M, Lukkarinen O. Postoperative urinary 
retention. I. Incidence and predisposing factors. Scand J Urol 
Nephrol. 1986;20:3:197–201.
 8. Tammela T, Kontturi M, Lukkarinen O. Postoperative urinary 
retention. II. Micturition problems after the first catheterization. 
Scand J Urol Nephrol. 1986;20(4):257–60.
 9. Slappendel R, Weber EW. Non-invasive measurement of bladder 
volume as an indication for bladder catheterization after ortho-
paedic surgery and its effect on urinary tract infections. Eur J 
Anaesthesiol. 1999;16(8):503–6.
 10. Sedor J, Mulholland SG. Hospital-acquired urinary tract infec-
tions associated with the indwelling catheter. Urol Clin North Am. 
1999;26(4):821–8.
 11. Carpenter FG. Impairment and restoration of rat urinary 
bladder responsiveness following distension. AmJPhysiol. 
1983;244(1):R106-13.
 12. Madersbacher H, Cardozo L, Chapple C, Abrams P, Toozs-Hob-
son P, Young JS, et al. What are the causes and consequences 
of bladder overdistension? ICI-RS 2011. NeurourolUrodyn. 
2012;31(3):317–21.
 13. Brouwer TA, Eindhoven BG, Epema AH, Henning RH. Validation 
of an ultrasound scanner for determing urinary volumes in surgical 
patients and volunteers. J Clin Monit Comput. 1999;15(6):379–85.
 14. Rosseland LA, Stubhaug A, Breivik H. Detecting postoperative 
urinary retention with an ultrasound scanner. Acta AnaesthesiolS-
cand. 2002;46(3):279–82.
 15. Byun SS, Kim HH, Lee E, Paick JS, Kamg W, Oh SJ. Accu-
racy of bladder volume determinations by ultrasonography: 
are they accurate over entire bladder volume range? Urology. 
2003;62(4):656–60.
 16. Hinze SR, Wiley J. Testing the limits of testing effects using com-
pletion tests. Memory. 2011;19(3):290–304.
 17. Pavlin DJ, Pavlin EG, Gunn HC, Taraday JK, Koerschen ME. 
Voiding in patients managed with or without ultrasound monitor-
ing of bladder volume after outpatient surgery. Anesth Analg. 
1999;89(1):90–7.
 18. Lamonerie L, Marret E, Deleuze A, Lembert N, Dupont M, Bon-
net F. Prevalence of postoperative bladder distension and urinary 
retention detected by ultrasound measurement. Br J Anaesth. 
2004;92(4):544–6.
 19. Bland JM, Altman DG. Statistical methods for assessing agree-
ment between two methods of clinical measurement. Lancet. 
1986;1:(8476):307–10.
 20. Medical Advisory Secretariat. Portable bladder ultrasound: an 
evidence-based analysis. Ontario Health Technol Assess Ser 2006; 
6(11):1–51.
 21. Huang YH, Bih LI, Chen SL, Tsai SJ, Teng CH. The accuracy 
of ultrasonic estimation of bladder volume: a comparison of 
portable and stationary equipment. Arch Phys Med Rehabil. 
2004;85(1):138–41.
 22. Marks LS, Dorey FJ, Macairan ML, Park C, DeKernion JB. Three-
dimensional ultrasound device for rapid determination of bladder 
volume. Adult Urol. 1997;50(3):341–8.
 23. Massagli TL, Cardenas DD, Kelly EW. Experience with port-
able ultrasound equipment and measurement of urine volumes: 
inter-user reliability and factors of patient position. JUrol. 
1989;142(4):969–71.
 24. Ouslander JG, Simmons S, Tuico E, Nigam JG, Fingold S, Bates-
Jensen B, et al. Use of a portable ultrasound device to measure 
post-void residual volume among incontinent nursing home resi-
dents. J Am Geriatr Soc. 1994;42(11):1189–92.
1126 Journal of Clinical Monitoring and Computing (2018) 32:1117–1126
1 3
 25. Ding YY, Sahadevan S, Pang WS, Choo PW. Clinical utility of a 
portable ultrasound scanner in the measurement of residual urine 
volume. Singapore Med J. 1996;37(4):365–8.
